BACKGROUND: Betaine has been shown to be antioxidantand methyl donor effects in our recent studies. OBJECTIVES: Inthe present study, the antioxidant and methyl donor properties ofbetaine in levodopa/benserazide-mediated hyperhomocysteinemiaand levodopa-induced oxidative stress in rat's kidney wereexamined. METHODS: Sprague-Dawley male rats were dividedinto levodopa (LD), Betaine (Bet.), levodop...

Objective(s): The aim of the present study was to evaluate antioxidant and methyl donor effects of betaine in cerebellum following levodopa and benserazide administration in rats. Materials and Methods: Sprague-Dawley male rats were treated with levodopa (LD), betaine (Bet), levodopa plus betaine (LD/Bet), levodopa plus benserazide (LD/Ben), levodopa plus betaine-benserazide (LD/Bet-Ben), and t...

background: betaine has been shown to be antioxidantand methyl donor effects in our recent studies. objectives: inthe present study, the antioxidant and methyl donor properties ofbetaine in levodopa/benserazide-mediated hyperhomocysteinemiaand levodopa-induced oxidative stress in rat's kidney wereexamined. methods: sprague-dawley male rats were dividedinto levodopa (ld), betaine (bet.), levodop...

objective(s): the aim of the present study was to evaluate antioxidant and methyl donor effects of betaine in cerebellum following levodopa and benserazide administration in rats. materials and methods: sprague-dawley male rats were treated with levodopa (ld), betaine (bet), levodopa plus betaine (ld/bet), levodopa plus benserazide (ld/ben), levodopa plus betaine-benserazide (ld/bet-ben), and t...

OBJECTIVES Degeneration of nigrostriatal neurons and subsequent striatal dopamine deficiency produce many of the symptoms of Parkinson disease (PD). Initially restoration of striatal dopamine with oral levodopa provides substantial benefit, but with long term treatment and disease progression, levodopa can elicit additional clinical symptoms, reflecting altered effects of levodopa in the brain....

Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease (PD). Oral levodopa has been widely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor (DDCI), which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-...

After 40 years of clinical experience, levodopa remains the gold standard treatment for Parkinson's disease (PD) despite the recent emergence of a host of new therapies. Some physicians are cautious when prescribing levodopa because of its association with motor complications. Evidence now suggests that levodopa-associated complications are a result of deep troughs in delivery of levodopa to th...

Metabolism of levodopa via the enzyme catechol-O-methyltransferase requires S-adenosylmethionine (SAM) as a methyl donor. SAM caused Parkinson disease (PD)-like symptoms in rodents. Therefore, SAM could contribute to a decreased efficacy of levodopa in the long term. SAM levels were significantly reduced in levodopa-treated PD patients, but they showed increased enzyme methionine adenosyl trans...